文献速递浆细胞疾病

脯氨酸通过下调脯氨酸脱氢酶促进多发性骨髓瘤增殖和耐药

Proline promotes proliferation and drug resistance of multiple myeloma by downregulation of proline dehydrogenase.
PubMed 文献 · Br J Haematol · 2023-02-08

该研究探讨骨髓微环境中氨基酸对多发性骨髓瘤进展的影响,发现多发性骨髓瘤患者骨髓微环境中脯氨酸升高且与不良预后相关,外源性脯氨酸调控骨髓瘤细胞增殖和耐药;脯氨酸升高源于骨胶原降解及脯氨酸脱氢酶(PRODH)表达异常,PRODH下调主要因启动子高甲基化伴DNMT3b高表达,过表达PRODH可抑制骨髓瘤细胞增殖和耐药并具治疗潜力。

要点

  • 多发性骨髓瘤患者骨髓微环境中脯氨酸升高,且与不良预后相关。
  • 外源性脯氨酸调控骨髓瘤细胞增殖和耐药。
  • PRODH下调主要因启动子高甲基化伴DNMT3b高表达,过表达PRODH抑制增殖和耐药。

核心结论

  • 脯氨酸是多发性骨髓瘤的关键代谢调节因子,PRODH调控多发性骨髓瘤进展,过表达PRODH具治疗潜力。

研究设计与样本

  • 研究探讨多发性骨髓瘤患者骨髓微环境中脯氨酸水平及其与预后的关系,并分析外源性脯氨酸对骨髓瘤细胞增殖和耐药的调控及PRODH的作用机制。

主要发现

  • 多发性骨髓瘤患者骨髓微环境中脯氨酸升高,且与不良预后相关。
  • 外源性脯氨酸调控多发性骨髓瘤细胞增殖和耐药。
  • 骨髓微环境中脯氨酸升高源于骨胶原降解及脯氨酸分解代谢关键酶PRODH表达异常。
  • PRODH在多发性骨髓瘤患者中下调,主要因启动子高甲基化伴DNMT3b高表达。
  • 过表达PRODH抑制多发性骨髓瘤细胞增殖和耐药。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Amino acids in the bone marrow microenvironment (BMME) are a critical factor for multiple myeloma (MM) progression. Here, we have determined that proline is elevated in BMME of MM patients and links to poor prognosis in MM. Moreover, exogenous proline regulates MM cell proliferation and drug resistance. Elevated proline in BMME is due to bone collagen degradation and abnormal expression of the key enzyme of proline catabolism, proline dehydrogenase (PRODH). PRODH is downregulated in MM patients, mainly as a result of promoter hypermethylation with high expression of DNMT3b. Thus, overexpression of PRODH suppresses cell proliferation and drug resistance of MM and exhibits therapeutic potential for treatment of MM. Altogether, we identify proline as a key metabolic regulator of MM, unveil PRODH governing MM progression and provide a promising therapeutic strategy for MM treatment.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Zhang J, Shi F, Liu X, et al. Proline promotes proliferation and drug resistance of multiple myeloma by downregulation of proline dehydrogenase. Br J Haematol. 2023. PMID: 36755409. doi:10.1111/bjh.18684

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。